Supported Projects
-
2022 - Continues Hemoglobinopatilerde Okside Hemoglobin ve Mitokondriyal Hasar İlişkili Moleküler Paternler DAMPs ve NAD ile Antioksidanların İnvitro Potansiyel Terapötik Etkileri
Project Supported by Higher Education Institutions
KARAKAŞ Z. (Executive), ÖZBEÖZ O., TANYILDIZ H. G., GÖKÇAY G. F., ÖZHAN G., GEDİKBAŞI A., et al.
-
2022 - 2025 An open -label, dose escalation, dose finding and proof of concept trial of SP-420 in subjects with transfusion-dependent B-thalassemia
-
2022 - 2024 Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects with Non-Transfusion Dependent Alpha -or Beta Thalasemia (ENERGIZE) AGIOS 17
Project Supported by Private Organizations in Other Countries
Karakaş Z. (Executive), Tanyıldız H. G.
-
2021 - 2023 Multicenter open label study to determine the dose and safety of oral asciminib in pediatric patients with Ph CHROMOSOME POSİTİVE CHRONİC MYELOİD LEUKEMİA İN CHRONİC PHASE previously treated with one or more tyrosine kinase inhibitors
-
2021 - 2023 A Phase 3b, multicenter, randomized, double blind, Placebo-controlled, parallel-group trial with an open label extension phase to evaluate efficacy and safety of avatrombopag for the treatmnet of trombocytopenia in pediatric subject with immune trombocytopenia for > 6 months
-
2021 - 2023 A phase 2 a, randomized open label study to evaluate the efficacy, safety tolerability, pharmocokinetics and pharmacodynamics of ISIS 702843 Administered subcutaneously to patients with non-transfusion depenmdent B- thalassemia intermedia
-
2017 - 2020 Relaps veya Refrakter Olgun B hücreli non-Hodgkin Lenfomalı Pediatrik ve Genç Yetişkin Hastalarda İbrutinibin Değerlendirildiği Randomize, Açık etiketli bir Güvenlilik ve Etkinilk Çalışması / 54179060LYM3003
Other International Funding Programs
Taçyıldız N.(Executive), Ünal E., Dinçaslan H., Tanyıldız H. G.